Home / Market News / $ADXN
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Addex Therapeutics Spin-Out Neurosterix Closes $105 Million Series B Financing

Nov 13, 2026, 8:08 AM UTC · Primary ticker $ADXN

Addex Therapeutics announced its spin-out, Neurosterix, secured $105 million in Series B funding. This financing validates Neurosterix's allosteric modulator approach for neuropsychiatric disorders and significantly increases the value of Addex's retained equity stake, providing a positive, albeit indirect, financial boost to Addex.

Addex Therapeutics reported that its spin-out company, Neurosterix, successfully closed a $105 million Series B financing round. This event is significant because it provides substantial capital for Neurosterix to advance its lead schizophrenia drug candidate, NTX-253, into Phase 2 clinical trials, as well as develop its broader pipeline. For Addex, this means its 8.5% equity interest in Neurosterix is now valued at $18.6 million, representing a substantial increase in the value of its non-core asset without any further investment. This development is positive for Addex as it validates its spin-out strategy and provides a clear valuation for a significant asset, potentially offering future monetization opportunities. The short-term implication is a positive sentiment boost for Addex, while the long-term opportunity lies in the potential for Neurosterix's pipeline success to further enhance the value of Addex's stake.

$ADXN positive Increased valuation of equity stake in Neurosterix
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.